Anadys Pharmaceuticals Overview
- Year Founded
-
1992
- Status
-
Acquired/Merged
- Employees
-
25
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$250M
Anadys Pharmaceuticals General Information
Description
Developer of biopharmaceuticals for the treatment of hepatitis C. The company's development pipeline includes ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase; and ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.
Contact Information
Corporate Office
- 5871 Oberlin Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 5871 Oberlin Drive
- Suite 200
- San Diego, CA 92121
- United States
Anadys Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 23-Nov-2011 | $250M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 11. IPO | 26-Mar-2004 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 10. Later Stage VC (Series C) | 20-Nov-2003 | 00.00 | 00000 | 00000 | Completed | Generating Revenue |
| 9. Later Stage VC (Series C) | 25-Jul-2002 | 000.00 | 00000 | 0000 | Completed | Generating Revenue |
| 8. Later Stage VC (Series B) | 000.00 | 00000 | 000.00 | Completed | ||
| 7. Later Stage VC (Series F) | 12-Dec-2000 | 000.00 | 000.00 | 000.00 | Completed | Product Development |
| 6. Later Stage VC (Series E) | 0000 | 000.00 | 00000 | Completed | Product Development | |
| 5. Later Stage VC (Series D) | 0000 | 000.00 | 00000 | Completed | Product Development | |
| 4. Later Stage VC (Series C) | $7.48M | $20.3M | 00000 | Completed | Product Development | |
| 3. Early Stage VC (Series B) | $6.58M | $12.8M | 000.00 | Completed | Product Development |
Anadys Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series A5 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 000.00 | 0.000 | |
| Series A4 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 000.00 | 0.00 | |
| Series A3 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 000.00 | 0.000 | |
| Series A2 | 6,579,086 | $0.010000 | $1 | $1 | 1x | $11.92 | 3.64% | |
| Series A1 | 6,556,325 | $0.010000 | $1 | $1 | 1x | $11.92 | 3.63% |
Anadys Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Anadys Pharmaceuticals Patents
Anadys Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2838257-A1 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | Inactive | 07-Jun-2011 | 0000000000 | |
| AU-2012268119-A1 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | Active | 07-Jun-2011 | 0000000000 | |
| US-20120316156-A1 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | Active | 07-Jun-2011 | 0000000000 | 0 |
| EP-2718273-A1 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | Inactive | 07-Jun-2011 | 0000000000 | 0 |
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | Inactive | 07-Jun-2011 | A61K31/549 | 0 |
Anadys Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Anadys Pharmaceuticals Former Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent International | PE/Buyout | Minority | 000 0000 | 000000 0 |
| Atlas Venture | Venture Capital | Minority | 000 0000 | 000000 0 |
| BioChem Pharma | Corporation | Minority | 000 0000 | 000000 0 |
| CDIB Capital Group | Venture Capital | Minority | 000 0000 | 000000 0 |
| Care Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
Anadys Pharmaceuticals FAQs
-
When was Anadys Pharmaceuticals founded?
Anadys Pharmaceuticals was founded in 1992.
-
Who is the founder of Anadys Pharmaceuticals?
Kleanthis Xanthopoulos Ph.D is the founder of Anadys Pharmaceuticals.
-
Where is Anadys Pharmaceuticals headquartered?
Anadys Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Anadys Pharmaceuticals?
Anadys Pharmaceuticals has 25 total employees.
-
What industry is Anadys Pharmaceuticals in?
Anadys Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Anadys Pharmaceuticals a private or public company?
Anadys Pharmaceuticals is a Private company.
-
What is the current valuation of Anadys Pharmaceuticals?
The current valuation of Anadys Pharmaceuticals is 00000.
-
What is Anadys Pharmaceuticals’s current revenue?
The current revenue for Anadys Pharmaceuticals is 000000.
-
How much funding has Anadys Pharmaceuticals raised over time?
Anadys Pharmaceuticals has raised $194M.
-
Who are Anadys Pharmaceuticals’s investors?
Advent International, Atlas Venture, BioChem Pharma, CDIB Capital Group, and Care Capital are 5 of 22 investors who have invested in Anadys Pharmaceuticals.
-
When was Anadys Pharmaceuticals acquired?
Anadys Pharmaceuticals was acquired on 23-Nov-2011.
-
Who acquired Anadys Pharmaceuticals?
Anadys Pharmaceuticals was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
